MX2009009743A - Polvos para reconstitucion. - Google Patents

Polvos para reconstitucion.

Info

Publication number
MX2009009743A
MX2009009743A MX2009009743A MX2009009743A MX2009009743A MX 2009009743 A MX2009009743 A MX 2009009743A MX 2009009743 A MX2009009743 A MX 2009009743A MX 2009009743 A MX2009009743 A MX 2009009743A MX 2009009743 A MX2009009743 A MX 2009009743A
Authority
MX
Mexico
Prior art keywords
reconstitution
powders
dispersed
treatment
relates
Prior art date
Application number
MX2009009743A
Other languages
English (en)
Inventor
Lieven Elvire Colette Baert
Peter Jozef Maria Van Remoortere
Elke Van Gyseghem
Mooter Guy Rene Jaak Van Den
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38055251&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009009743(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of MX2009009743A publication Critical patent/MX2009009743A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Esta invención se refiere a polvos para reconstitución que comprenden el NNRTI TMC278 disperso en ciertos polímeros solubles en agua, que puede aplicarse en el tratamiento contra la infección por VIH.
MX2009009743A 2007-03-14 2008-03-14 Polvos para reconstitucion. MX2009009743A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07104082 2007-03-14
PCT/EP2008/053056 WO2008110619A1 (en) 2007-03-14 2008-03-14 Powders for reconstitution

Publications (1)

Publication Number Publication Date
MX2009009743A true MX2009009743A (es) 2009-09-23

Family

ID=38055251

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009743A MX2009009743A (es) 2007-03-14 2008-03-14 Polvos para reconstitucion.

Country Status (18)

Country Link
US (1) US8916558B2 (es)
EP (1) EP2043608B1 (es)
JP (1) JP5554571B2 (es)
KR (1) KR101580297B1 (es)
CN (1) CN101636149B (es)
AP (1) AP2964A (es)
AR (2) AR065720A1 (es)
AU (1) AU2008225774B2 (es)
BR (1) BRPI0808897B8 (es)
CA (1) CA2676981C (es)
CL (1) CL2008000746A1 (es)
ES (1) ES2535162T3 (es)
IL (1) IL199874A (es)
MX (1) MX2009009743A (es)
RU (1) RU2477133C2 (es)
TW (1) TWI494133B (es)
WO (1) WO2008110619A1 (es)
ZA (1) ZA200906344B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
TWI494133B (zh) 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
CN108210469A (zh) 2011-04-15 2018-06-29 詹森药业有限公司 冻干药物纳米混悬剂
EP2911651B1 (en) * 2012-09-27 2016-06-22 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
EP3993799A1 (en) * 2019-07-03 2022-05-11 Janssen Sciences Ireland Unlimited Company Methods of treating hiv in pediatric patients with rilpivirine
CN113440529B (zh) * 2020-03-25 2023-11-14 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
CN114392241B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种利匹韦林片及其制备方法
WO2023203257A1 (en) * 2022-04-22 2023-10-26 Janssen Sciences Ireland Unlimited Company Freeze dried compositions

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089818A (en) * 1960-06-02 1963-05-14 Baxter Laboratories Inc Water dispersible antibiotics
US5182111A (en) 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
US5368864A (en) * 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
DK0489181T3 (da) * 1990-07-19 1996-11-18 Otsuka Pharma Co Ltd Fast præparat
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2121129A1 (en) 1991-10-29 1993-05-13 Patrick Soon-Shiong Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
DK0639971T3 (da) 1992-05-13 2000-03-20 Wellcome Found Terapeutiske kombinationer
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
TW401303B (en) 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
CA2383233C (en) 1999-09-21 2010-06-08 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
PL207590B1 (pl) 1999-09-24 2011-01-31 Janssen Pharmaceutica Nv Cząstka stanowiąca dyspersję stałą oraz postać dawkowania, sposób ich otrzymywania i zastosowanie
US6743446B2 (en) 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TWI284048B (en) 2000-01-27 2007-07-21 Zentaris Ag Compressed microparticles for dry injection
WO2001074329A2 (en) 2000-03-30 2001-10-11 Bristol-Myers Squibb Company Sustained release beadlets containing stavudine
US20040115268A1 (en) 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
DE10050199A1 (de) 2000-10-11 2002-04-25 Ethicon Gmbh Flächiges Implantat mit im Ultraschall detektierbaren Elementen
CN1487935A (zh) * 2000-12-11 2004-04-07 ����ҩƷ��ҵ��ʽ���� 改良型水溶性药物组合物
ATE444060T1 (de) * 2001-06-22 2009-10-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AU2002364701B8 (en) 2001-11-20 2006-06-22 Alkermes, Inc. Compositions for sustained action product delivery
CN102702111B (zh) 2002-08-09 2014-12-17 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
US7497855B2 (en) 2002-09-04 2009-03-03 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
EP1567133B1 (en) 2002-11-08 2007-05-02 Glaxo Group Limited Pharmaceutical antiviral compositions
CA2506316A1 (en) 2002-11-15 2004-06-03 Tibotec Pharmaceuticals Ltd. Substituted indolepyridinium as anti-infective compounds
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
AU2004210081B2 (en) 2003-02-07 2009-11-26 Janssen Pharmaceutica N.V. Pyrimidine derivatives for the prevention of HIV infection
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
AU2005253957B2 (en) 2004-06-08 2011-08-25 Janssen Pharmaceutica Nv Pharmaceutical compositions
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
CA2577288C (en) 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
ATE508748T1 (de) 2004-09-02 2011-05-15 Janssen Pharmaceutica Nv Salz von 4-ää4-ää4-(2-cyanoethenyl)-2,6- dimethylphenylüaminoü-2- pyrimidinylüaminoübenzonitril.
EP2623095A1 (en) 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
TW200710091A (en) * 2005-04-11 2007-03-16 Tibotec Pharm Ltd (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
AU2006235565A1 (en) 2005-04-11 2006-10-19 The Board Of Trustees Of The Leland Stanford Junior University Multi-layer structure having a predetermined layer pattern including an agent
WO2006131806A2 (en) 2005-06-07 2006-12-14 Pfizer Products Inc. Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
CN101277682B (zh) * 2005-07-28 2015-07-29 Isp投资有限公司 无定形依发韦仑及其生产
KR101501475B1 (ko) 2006-01-20 2015-03-19 얀센 알 앤드 디 아일랜드 Ｔｍｃ２７８을 이용한 ｈｉｖ 감염의 장기간 요법
PL2029110T3 (pl) 2006-06-06 2012-03-30 Janssen Sciences Ireland Uc Proces wytwarzania suszonych rozpyłowo formulacji TMC125
AP2618A (en) 2006-06-23 2013-03-18 Tibotec Pharmaceutical Ltd Aqueous suspensions of TMC278
US20080081064A1 (en) 2006-09-28 2008-04-03 Surmodics, Inc. Implantable Medical Device with Apertures for Delivery of Bioactive Agents
TWI494133B (zh) 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
US8426434B2 (en) 2007-07-12 2013-04-23 Tibotec Pharmaceuticals Ltd. Crystalline form of 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile
WO2009046299A2 (en) 2007-10-04 2009-04-09 Boston Scientific Scimed, Inc Implantable drug depot for intrathecal drug delivery system for pain management
US20110257111A1 (en) 2008-10-24 2011-10-20 Harbeson Scott L Hydroxyethlamino Sulfonamide Derivatives

Also Published As

Publication number Publication date
AU2008225774B2 (en) 2014-04-10
KR101580297B1 (ko) 2015-12-24
EP2043608B1 (en) 2015-01-21
AU2008225774A1 (en) 2008-09-18
IL199874A0 (en) 2010-04-15
AR065720A1 (es) 2009-06-24
RU2477133C2 (ru) 2013-03-10
BRPI0808897B1 (pt) 2020-10-20
ZA200906344B (en) 2015-04-29
CA2676981C (en) 2015-01-13
ES2535162T3 (es) 2015-05-05
CA2676981A1 (en) 2008-09-18
RU2009137911A (ru) 2011-04-20
US8916558B2 (en) 2014-12-23
JP2010520918A (ja) 2010-06-17
KR20090119964A (ko) 2009-11-23
AR114086A2 (es) 2020-07-22
TW200911303A (en) 2009-03-16
US20100120795A1 (en) 2010-05-13
AP2964A (en) 2014-09-30
WO2008110619A1 (en) 2008-09-18
BRPI0808897A2 (pt) 2014-09-02
IL199874A (en) 2016-02-29
JP5554571B2 (ja) 2014-07-23
CN101636149A (zh) 2010-01-27
AP2009004969A0 (en) 2009-10-31
EP2043608A1 (en) 2009-04-08
CN101636149B (zh) 2014-08-06
BRPI0808897B8 (pt) 2021-05-25
CL2008000746A1 (es) 2008-09-22
TWI494133B (zh) 2015-08-01

Similar Documents

Publication Publication Date Title
MX2009008617A (es) Uso de antagonistas de interleucina-23 para el tratamiento de infeccion.
MX2009009743A (es) Polvos para reconstitucion.
HK1216880A1 (zh) 某些***並吡啶化合物、其組合物和它們在治療癌症中的用途
EP2569330A4 (en) CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF
RS53124B (en) USE OF BETANECOL FOR THE TREATMENT OF XEROSOMOMY
GEP20156230B (en) Forms of rifaximin and usage thereof
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
WO2012076293A9 (de) Zubereitungen enthaltend polysiloxane mit stickstoffhaltigen gruppen
MX2022011699A (es) Compuestos para tratar la atrofia muscular espinal.
WO2008127364A3 (en) Antiviral compounds and use thereof
MX2012007507A (es) Compuestos de heteroarilo y usos de los mismos.
IN2015DN03327A (es)
MX2008001652A (es) Copolimeros de poliamonio-polisiloxano.
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
MX350234B (es) Compuestos de enlace especificos de bacterias gram-positivas.
MX357834B (es) Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal.
MX2014010406A (es) Compuestos para tratar atrofia muscular espinal.
MX346423B (es) Conjugados de polimeros zwiterionicos multifuncionales.
MX358514B (es) Compuestos para tratar la atrofia muscular espinal.
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2010083385A3 (en) Compounds for reducing drug resistance and uses thereof
MX356210B (es) Formulaciones de polimero acrilico.
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
PH12015501088A1 (en) Dimeric compounds
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use

Legal Events

Date Code Title Description
FG Grant or registration